| Coronavirus vaccines: five key questions as trials begin #MMPMID32203367Callaway ENature 2020[Mar]; 579 (7800): 481 PMID32203367show ga
ä|*Biomedical Research[MESH]|*Disease Models, Animal[MESH]|Animals[MESH]|COVID-19[MESH]|COVID-19 Vaccines[MESH]|Clinical Trials, Phase I as Topic[MESH]|Coronavirus Infections/*immunology/*prevention & control[MESH]|Guinea Pigs[MESH]|Humans[MESH]|Immunologic Memory/*immunology[MESH]|Macaca mulatta/immunology/virology[MESH]|Mice[MESH]|Pandemics/*prevention & control[MESH]|Pneumonia, Viral/*immunology/*prevention & control[MESH]|Risk Assessment[MESH]|Spike Glycoprotein, Coronavirus/biosynthesis/genetics/immunology[MESH]|T-Lymphocytes/immunology[MESH]|Time Factors[MESH]
DeepDyve Pubget Overpricing |
|